secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001193125-25-278679
Event type: debt
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Cogent Biosciences prices 9.7M share offering at $31 and $230M 1.625% convertible notes due 2031 for ~$475M net
--------------------------------------------------------------------------------

- Equity offering of 9,677,420 shares at $31.00 per share, upsized from $200M, with underwriters exercising over-allotment for additional 1,451,613 shares.
- Convertible notes offering of $200M aggregate principal (upsized to $230M) of 1.625% senior notes due 2031, conversion premium ~45% above equity offering price.
- Combined net proceeds expected ~$475.3M, to be used to repay $50M term loan and fund development/commercialization of bezuclastinib.
- Offerings led by J.P. Morgan, Jefferies, Leerink Partners, and Guggenheim Securities for equity; Jefferies and J.P. Morgan for notes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000119312525278679/0001193125-25-278679-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000119312525278679/d46097d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-278679

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer